Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

69
Uranium Mining: The Competitive Landscape

2018-06-25 seekingalpha
The operators in the Athabasca Basin, Canada, enjoy the highest-grade uranium deposits and have a geological edge over other uranium districts.
PALAY PEN RIO LAM BLT AZZ TOEYF SYH PDN UEXCF PALAF NXE UEC EFR BMN UUUU.WS LMRXF FSY DNN PWURF CVV RIO BBL GVXXF BHPLF FCU SYHBF DYLLF RIO NXGEF BKY ISENF CVVUF WSTRF RTPPF FOSYF TOE RTNTF CCJ UUUU DYL PENMF UWEFF KVLQF TGRUF MGAFF PDN BHPBF FCUUF EU URG DML BKY MGA PUMGF BHP BNNLF 9888 BHP LAM

0
Bannerman Resources' managing director shares expert insights on uranium market

2018-06-19 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) managing director Brandon Munro speaks to Proactive Investors about the company's Etango Uranium Project in Namibia, and also provides insights on the wider uranium market.
BNNLF BMN

0
A$8 Million Capital Raising Heavily Oversubscribed

2018-06-08 globenewswire
PERTH, Australia, June 08, 2018 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN) (NSX:BMN) (Bannerman or the Company) is pleased to announce that it has received commitments to raise A$8 million gross proceeds through the placement of 173,913,043 new Bannerman shares at an issue price of A$0.046 per share (Placement). The Placement was made to both institutional and sophisticated investors.
BNNLF BMN

0
Bannerman Resources in heavily oversubscribed raising as institutions build positions

2018-06-08 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) continues to be well supported by the investment community, and will now raise $8 million in a heavily oversubscribed placement at 4.6 cents.
BNNLF BMN

0
Bannerman Resources in heavily oversubscribed raising as intuitions build positions

2018-06-08 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) continues to be well supported by the investment community, and will now raise $8 million in a heavily oversubscribed placement at 4.6 cents.
BNNLF BMN

0
Bannerman Resources to lift cash position as uranium market awakens

2018-06-06 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN) remains focused on the Etango project in Namibia, which hosts a resource of 271 million pounds of uranium.
BNNLF BMN

16
Bannerman Resources to benefit from cost reductions at Etango

2018-05-08 proactiveinvestors.com.au
Bannerman Resources Limited (ASX:BMN), like most players in the uranium sector, has had its share of challenges.
RTPPF RIO RIO BNNLF RIO RTNTF BMN

16
Bannerman Resources continues to progress uranium project in Namibia

2018-04-30 proactiveinvestors.com.au
Bannerman Resources Limited (ASX:BMN) is continuing to make steady progress at its Etango Uranium Project in Namibia, successfully completing a membrane study during the March quarter.
PDN PALAY PALAF RTPPF RIO RIO PDN BNNLF RIO RTNTF BMN

16
Membrane Study delivers cost savings to Etango

2018-04-11 globenewswire
PERTH, Australia, April 11, 2018 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN) (NSX:BMN) (Bannerman or the Company) is pleased to announce that the Etango Membrane Study has been completed successfully, delivering substantial reagent/operating cost reductions along with forecast capital savings, the final quantum of which is to be confirmed in the Etango Definitive Feasibility Study Update (DFS Update).
RTPPF RIO RIO BNNLF RIO RTNTF BMN

0
Bannerman Resources membrane study delivers cost savings to Etango

2018-04-11 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN) has completed its membrane study, which has delivered cost savings for its Etango Uranium Project in Namibia.
BNNLF BMN

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...